SAN DIEGO - Viracta Therapeutics, Inc. (NASDAQ: VIRX), a precision oncology company specializing in virus-related cancers, has announced it will terminate its employees and begin winding down ...

SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated ...

Viracta Therapeutics, Inc. (NASDAQ:VIRX), a pharmaceutical company with a market capitalization of just $6 million, is set to be delisted from the Nasdaq Stock Market LLC, with trading of its common ...

Viracta Therapeutics, Inc. (NASDAQ:VIRX), a pharmaceutical company with a market capitalization of just $6 million, is set to be delisted from the Nasdaq Stock Market LLC, with trading of its ...

在动荡的市场交易中，Sunesis Pharmaceuticals的股票VIRX跌至52周新低，触及0.08美元的低位。根据InvestingPro数据显示，公司市值已萎缩至仅602万美元，其财务健康指标显示整体评分为1.3（满分5分），情况令人担忧。这次显著下跌凸显了这家生物制药公司正经历艰难时期 ...

Figuring out how to stop post-nasal drip quickly can help mitigate the other uncomfortable symptoms of the phenomenon, like sore throat or stomach upset. While post-nasal drip is typically a mild ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine-derived nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...

But hidden at your pharmacy among the potpourri of cough drops and cold remedies, you can find a low-risk treatment that actually may help: nasal irrigation devices. Several small studies suggest ...

The global landscape of neurological health is undergoing a transformative moment with a pioneering nasal spray that could potentially revolutionize Alzheimer‘s disease management. As ...

Viracta Therapeutics, Inc. (NASDAQ:VIRX), a biopharmaceutical company with a market capitalization of $6.74 million, has entered into a forbearance agreement with its lenders, securing a temporary ...